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ScheduleCarﬁlzomib is a proteasome inhibitor that binds selectively and irreversibly to its target. In July 2012, car-
ﬁlzomib received accelerated approval in the United States for the treatment of relapsed and refractory
multiple myeloma. Based on emerging preclinical data and clinical results, the total dose, infusion time,
and administration schedule of carﬁlzomib have evolved during phase I and phase II clinical studies, with
the aim of optimizing the risk-beneﬁt proﬁle of the agent. Based on in vitro and in vivo ﬁndings and
encouraging phase I tolerability data, a consecutive-day, twice-weekly dosing schedule was implemented
early in the development program. Other phase II studies have led to further reﬁnements in the dosing
schedule of carﬁlzomib, resulting in the current approved schedule for carﬁlzomib to be administered
intravenously over 2–10 min on 2 consecutive days each week for 3 weeks of a 28-day cycle. Prolonged
infusion over 30 min has also been assessed in clinical studies to enable the use of higher carﬁlzomib
doses with the aim of improving drug tolerability and efﬁcacy. These data collectively informed the dos-
ing and scheduling schemas for carﬁlzomib in ongoing trials, including phase I and II studies of combi-
nation regimens, and the randomized phase III trials ASPIRE, FOCUS, ENDEAVOR, and CLARION.
Additional studies are underway to examine alternative dosing schedules (e.g., once-weekly dosing
[CHAMPION-1]).
 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Carﬁlzomib is a selective proteasome inhibitor that produces
sustained inhibition of the chymotrypsin-like activity of the consti-
tutive proteasome and immunoproteasome [1,2], proteasomal
variants that are important targets in the treatment of hematologic
malignancies [3]. In phase I and phase II clinical studies, carﬁlzo-
mib demonstrated robust and durable efﬁcacy and an acceptable
safety and tolerability proﬁle in patients with relapsed and/or
refractory multiple myeloma (MM) [4–10], leading to the acceler-
ated approval of carﬁlzomib in the United States in 2012 for the
treatment of relapsed and refractory MM [11]. This paper reviews
the clinical development of carﬁlzomib (Tables 1 and 2; Fig. 1),
with a particular emphasis on the evolution of dose and schedule
during phase I and phase II clinical studies in relapsed and/or
refractory MM, including the pivotal PX-171-003-A1 (003-A1)
clinical study [11].Preclinical data supporting phase I studies
Preclinical studies provided the basis for phase I clinical testing
of carﬁlzomib in the treatment of hematologic malignancies (Onyx
Pharmaceuticals, unpublished results) [1,3,4]. In rodents and mon-
keys, dosing on 2 consecutive days (QD  2; e.g., days 1, 2, 8, 9, 15,
and 16 of a 28-day cycle) or 5 consecutive days (QD  5; e.g., days
1–5 of a 14-day cycle) using bolus intravenous (IV) schedules led to
cumulative inhibition of proteasome activity (Onyx Pharmaceuti-
cals, unpublished results) [1]. In further support of consecutive dai-
ly dosing, mice with established xenograft tumors that received
carﬁlzomib (5–10 mg/kg) on a consecutive day schedule (i.e., days
1 and 2) demonstrated reductions in tumor growth, while a once-
weekly or twice-weekly (i.e., days 1 and 4) schedule that allowed
for full proteasome recovery between doses was less effective
[1]. As doses up to 5 mg/kg (QD  2) and doses up to 2 mg/kg
(QD  5) were well tolerated in tumor-bearing animals [1], both
schedules warranted further investigation in clinical trials. A start-
ing dose level of 1.2 mg/m2, representing one-tenth of the severely
toxic dose in 10% of rats [4], was selected for phase I investigation.
Table 1
Completed clinical studies of carﬁlzomib in MM.
PX-171-001 PX-171-002 PX-171-003-A0 PX-171-003-A1 PX-171-004
BTZ-treated
PX-171-004
BTZ-naive
PX-171-005
Phase I I II II II II II
Registration number – NCT00150462 NCT00511238 NCT00511238 NCT00530816 NCT00530816 NCT00721734
Age, y P18 P18 P18 P18 P18 P18 P18
Diagnosis Relapsed or
refractory MMa
Relapsed or
refractory MMa
Relapsed and
refractory IgG or
IgA MM
Relapsed and
refractory IgG, IgA,
IgE, or IgD MM
Relapsed and/or
refractory MM
Relapsed and/or
refractory MM
Relapsed and/or
refractory MM
Number of prior
anti-MM therapies
P2 P2 P2 P2 1–3 1–3 (no prior BTZ) P2
ECOG PS 0–2 0–2 0–2 0–2 0–2 0–2 0–2
Hematologic
parameters
WBCsP 2000/
mm3, ANCP 1000/
mm3, HbP 8.0 g/
dL,
plateletsP 50,000/
mm3
WBCsP 2000/
mm3, ANCP 1000/
mm3, HbP 8.0 g/
dL,
plateletsP 50,000/
mm3
WBCsP 2000/
mm3, ANCP 1000/
mm3, HbP 8.0 g/
dL,
plateletsP 50,000/
mm3
WBCsP 2000/
mm3, ANCP 1000/
mm3, HbP 8.0 g/
dL,
plateletsP 50,000/
mm3
WBCsP 2000/
mm3, ANCP 1000/
mm3, HbP 8.0 g/
dL,
plateletsP 50,000/
mm3
WBCsP 2000/
mm3, ANCP 1000/
mm3, HbP 8.0 g/
dL,
plateletsP 50,000/
mm3
WBCsP 2000/
mm3, ANCP 1000/
mm3, HbP 7.0 g/
dL,
plateletsP 30,000/
mm3
Organ function Adequate hepatic
function;
CrClP 30 mL/min
Adequate hepatic
function;
CrClP 30 mL/min
Adequate hepatic
function;
CrClP 30 mL/min
Adequate hepatic
function;
CrClP 30 mL/min
Adequate hepatic
function;
CrClP 30 mL/min
Adequate hepatic
function;
CrClP 30 mL/min
Adequate hepatic
function; patients
were grouped
according to renal
function, ranging
from normal to
chronic dialysis
Dosing schedule QD  5b QD  2c QD  2c QD  2c QD  2c QD  2c QD  2c
Carﬁlzomib dose,
cycle 1 (mg/m2)
1.2–20.0 1.2–27.0 (dose-
escalation phase);
20 on D1, 2 then 27
thereafter (dose-
expansion phase)
20 20 20 20 15
Carﬁlzomib dose,
cycle 2 and
beyond (mg/m2)
1.2–20.0 1.2–27.0 (dose-
escalation phase);
27 (dose-
expansion phase)
20 27 20 20, 27 20, 27d
Additional treatmente None None (dose-
escalation phase);
none or
dexamethasone
(20 mg) before
each carﬁlzomib
dose for up to 12
cycles (dose-
expansion phase)
None None None None None
Infusion time, min 1–2 1–2 2–10 2–10 2–10 2–10 2–10
ANC, absolute neutrophil count; BTZ, bortezomib; CrCl, creatinine clearance; D, day; ECOG PS, Eastern Cooperative Oncology Group performance status; Hb, hemoglobin; Ig,
immunoglobulin; min, minutes; MM, multiple myeloma; QD, consecutive days; WBCs, white blood cells; y, year.
a Patients with non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, or Waldenström’s macroglobulinemia were also enrolled.
b D1–5 of 14-day cycle.
c D1, 2, 8, 9, 15, 16 of 28-day cycle.
d 20 mg/m2 for cycle 2 and 27 mg/m2 for cycle 3 and beyond, if tolerated.
e Patients in 002, 003, 004, 005, and the single-agent cohorts of 007 also received dexamethasone (4 mg) as premedication before each dose of carﬁlzomib in cycle 1 as
prophylaxis against ﬁrst-dose infusion reactions.
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The initial phase I studies PX-171-001 (001) and PX-171-002
(002; NCT00150462) were undertaken in parallel to assess the
safety, pharmacokinetics (PK), pharmacodynamics (PD), and
preliminary efﬁcacy of carﬁlzomib in patients with relapsed or
refractory hematologic malignancies (see Table 1) [4,5].
PX-171-001
The phase I study 001 began in October 2005 (ﬁrst patient, ﬁrst
visit [FPFV]) and ended in July 2007 (last patient, last visit [LPLV];
see Fig. 1). In 001, single-agent carﬁlzomib was administered on a
QD  5 schedule as an IV infusion over 1–2 min (see Table 1) [4].
Patients were enrolled in cohorts of 3 to receive carﬁlzomib in a
dose-escalating fashion to a maximum planned dose of 20 mg/m2
(1.2, 2.4, 4, 6, 8.4, 11, 15, and 20 mg/m2).PX-171-002 (NCT00150462)
The phase I study 002 began in September 2005 (FPFV) and
ended in January 2009 (LPLV; see Fig. 1). In 002, single-agent car-
ﬁlzomib was administered on a QD  2 schedule as an IV infusion
over 1–2 min for a maximum of 12 cycles [5]. As in 001, escalating
dose levels started at 1.2 mg/m2 and increased to 2.4, 4, 6, 8.4, 11,
15, and 20 mg/m2; in addition, 002 had a maximum planned dose
of 27 mg/m2.
Dose escalation in 002 was followed by dose expansion at the
maximum planned or maximum tolerated dose (MTD). The dose
expansion phase included a single-agent carﬁlzomib cohort and a
carﬁlzomib plus dexamethasone cohort. Patients received carﬁlzo-
mib at 20 mg/m2 on days 1 and 2 of cycle 1, and were to be dose-
escalated to a target dose of 27 mg/m2 thereafter (20/27-mg/m2
cohort). In the carﬁlzomib plus dexamethasone cohort, patients re-
ceived 20 mg oral dexamethasone before each carﬁlzomib dose.
Table 2
Key ongoing studies of carﬁlzomib in MM that were informed by the results of phase I/II trials.
PX-171-006 PX-171-007 CARMYSAP ASPIRE FOCUS ENDEAVOR CLARION CHAMPION-1
Phase Ib/II Ib/II I/II III III III III I/II
Registration number NCT00603447 NCT00531284 NCT01279694 NCT01080391 NCT01302392 NCT01568866 NCT01818752 NCT01677858
Age, y P18 P18 >65 P18 P18 P18 P18 P18
Diagnosis Relapsed or progressive MM Relapsed and/or
refractory MMa
Newly diagnosed,
transplant-
ineligible MM
Relapsed MM Relapsed and
refractory MM
Relapsed MM Newly diagnosed,
transplant-
ineligible MM
Relapsed or refractory
MM
Number of prior anti-MM
therapies
1–3 P2 0 1–3 P3 1–3 0 1–3
ECOG PS 0–2 0–2 0–2 0–2 0–2 0–2 0–2 0 or 1
Hematologic parameters ANCP 1000/mm3,
HbP 8.0 g/dL,
plateletsP 50,000/mm3
ANCP 1000/mm3,
plateletsP 30,000/
mm3, HbP 7.0 g/dL
ANCP 1000/mm3,
plateletsP 50,000/
mm3
ANCP 1000/mm3,
HbP 8.0 g/dL,
plateletsP 50,000/
mm3
WBCsP 1500/
mm3, ANCP 1000/
mm3, HbP 7.5 g/
dL,
plateletsP 30,000/
mm3
ANCP 1000/mm3,
HbP 8.0 g/dL,
plateletsP 50,000/
mm3
ANCP 1000/mm3,
HbP 8.0 g/dL,
plateletsP 50,000/
mm3
ANCP 1000/mm3,
HbP 8.0 g/dL,
plateletsP 50,000/
mm3
Organ function Adequate hepatic function;
CrClP 50 mL/min
Adequate hepatic
function;
CrClP 20 mL/min
Adequate hepatic
function;
CrCl > 30 mL/min
Adequate hepatic
function;
CrClP 50 mL/min
Adequate hepatic
function;
CrClP 15 mL/min
Adequate hepatic
function;
CrClP 15 mL/min
Adequate hepatic
function;
CrClP 15 mL/min
Adequate hepatic
function;
CrClP 30 mL/min
Dosing schedule QD  2b QD  2b QD  2c QD  2b QD  2b QD  2b QD  2c QWd
Carﬁlzomib dose, cycle 1
(mg/m2)
15, 20, or 20 on D1, 2 only,
then 27 thereafter (dose-
escalation phase); 20 on D1,
2, then 27 thereafter (dose-
expansion phase)
20 on D1, 2, then 36–
70 thereafter (dose-
escalation phase) or
45–56 thereafter
(dose-expansion
phase)
20 on D1, 2, then
20–45 thereafter
(dose-escalation
phase) or 36
thereafter (dose-
expansion phase)
20 on D1, 2, then
27 thereafter
20 on D1, 2, then
27 thereafter
20 on D1, 2, then
56 thereafter
20 on D1 & 2 of
cycle 1, then 36
thereafter
20 on D1 of cycle 1,
then 45–88 thereafter
(dose-escalation
phase); or MTD
thereafter (dose-
expansion phase)
Carﬁlzomib dose, cycle 2
and beyond (mg/m2)
15, 20, or 27 (dose-escalation
phase) or 27 (dose-expansion
phase) through cycle 12, then
biweekly (D1, 2, 15, and 16)
for subsequent cycles
36–70 (dose-
escalation phase);
45–56 (dose-
expansion phase)
20–45 (dose-
escalation phase);
36 (dose-expansion
phase)
27 through cycle
12, then biweekly
(D1, 2, 15, and 16)
for cycles 13–18
27; may begin
biweekly dosing
(D1, 2, 15, and 16)
in cycle 10 at
investigator
discretion
56 36 45–88 (dose-
escalation phase);
MTD (dose-expansion
phase)
Additional treatment Lenalidomide (10, 15, 20, or
25 mg [dose-escalation
phase]; 25 mg [dose-
expansion phase] on D1–21)
and low-dose dexamethasone
(40 mg/week)
None; or weekly
low-dose
dexamethasone
(40 mg) from cycle 1
onwards
Melphalan (9 mg/
m2) and prednisone
(60 mg/m2) on D1–
4
Lenalidomide
(25 mg on D1–21)
and low-dose
dexamethasone
(40 mg/week) for
all cycles
None Low-dose
dexamethasone
(40 mg/week)
Melphalan (9 mg/
m2) and
prednisone
(60 mg/m2) on D1–
4
Low-dose
dexamethasone
(40 mg on D1, 8, 15,
and 22 of cycle 1–8,
and on D1, 8, 15 of
cycle 9 and beyond)
Infusion time, min 2–10 2–10; or 30 30 2–10 2–10 30 30–60 30
ANC, absolute neutrophil count; CrCl, creatinine clearance; D, day; ECOG, Eastern Cooperative Oncology Group performance status; Hb, hemoglobin; min, minutes; MM, multiple myeloma; MTD, maximum tolerated dose; QD,
consecutive days; QW, once-weekly dosing; WBCs, white blood cells; y, year.
a Patients with solid tumors and refractory or rituximab-intolerant lymphoma were also enrolled.
b D1, 2, 8, 9, 15, 16 of 28-day cycle.
c D1, 2, 8, 9, 22, 23, 29, 30 of 42-day cycle.
d D1, 8, 15 of 28-day cycle.
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003-A0 
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FOCUS CFZ vs BSC 
004 (BTZ-treated) 
001 
002 
Completed 
Phase I 
Studies 
Completed 
Phase II 
Studies 
007 (2-10 min) 
Ongoing 
Phase 
Ib/II 
Studies 
CARMYSAP (CMP; elderly) 
Ongoing 
Phase III 
Studies 
007 (Cd) 
2004 
LPFV 
Estimated Study Completion 
ENDEAVOR Cd vs Vd 
CLARION CMP vs VMP 
CHAMPION-1 Cd (QW) 
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2005 2006 2018 2019 
ASPIRE CRd vs Rd 
004 (BTZ-naive) 
005 (varying renal 
function) 
006 (CRd) 
007 (30 min) 
Fig. 1. Clinical timeline for carﬁlzomib. Safety and efﬁcacy results from phase I and II trials informed the study design of the phase III trials. BSC, best supportive care; BTZ,
bortezomib; Cd, carﬁlzomib and dexamethasone; CMP, carﬁlzomib, melphalan, and prednisone; CRd, carﬁlzomib, lenalidomide, and dexamethasone; LPLV, last patient, ﬁrst
visit; min, minutes; QW, once-weekly dosing; Rd, lenalidomide and dexamethasone; Vd, bortezomib and dexamethasone; VMP, bortezomib, melphalan, and prednisone.
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hort who did not respond or failed to achieve at least a partial re-
sponse by cycle 2 or a complete response by cycle 4 were
permitted to receive 20 mg oral dexamethasone before each dose
of carﬁlzomib (120 mg/cycle).
Safety and tolerability
Differences in the tolerability proﬁles of both dosing schedules
were apparent. In 001, the most common toxicities were grade 1/2
fatigue and gastrointestinal events, whereas hematologic toxicities
were more frequently observed in 002. Notably, grade 3/4 periph-
eral neuropathy was not reported at high rates in either study, a
ﬁnding that was also observed in later studies. The 001 study
established the MTD of carﬁlzomib as 15 mg/m2; in contrast, the
MTD was not reached in the 002 study. Based on evidence of
anti-MM activity at the 27-mg/m2 dose and a preliminary analysis
of safety data, the dose-expansion phase of the 002 trial was
amended to evaluate the escalated dosing approach noted above
(dose escalation from 20 to 27 mg/m2 on day 8 of cycle 1). This ap-
proach was found to be well tolerated in 6 patients with no dose-
limiting toxicities observed.
In a small number of patients, administration of carﬁlzomib on
either dosing schedule was associated with what was considered at
the time to be tumor lysis syndrome (TLS)-like reactions during
cycle 1 and ﬁrst-dose-like effects. TLS-like reactions werecharacterized by a constellation of symptoms that included
increased lactate dehydrogenase, hyperuricemia, hyperphosphate-
mia, hypocalcemia, hyperkalemia, and renal failure. First-dose-like
effects included the following events/symptoms: inﬂuenza-like
illness, cytokine release syndrome, infusion-related reaction, pyr-
exia, chills, feeling hot, ﬂushing, dyspnea, hypotension, hypoxia,
arthralgia, or myalgia. The initial concerns regarding TLS and
ﬁrst-dose-like effects were mitigated in patients receiving
single-agent carﬁlzomib by the prophylactic use of very-low-dose
dexamethasone (4 mg; patients receiving dexamethasone 20 mg
before each dose of carﬁlzomib did not receive the prophylactic
dose) and hydration in cycles 1 and 2. Patients also received
250–500 mL IV saline or other appropriate IV ﬂuid prior to each
dose, with an additional 250–500 mL as needed after administra-
tion of carﬁlzomib. IV hydration could be continued beyond cycle
2 if deemed necessary [5].Pharmacokinetics/pharmacodynamics
PK assessments from both phase I studies revealed no signiﬁ-
cant differences between the 2 dosing schedules in key PK param-
eters (e.g., maximum concentration [Cmax], half-life [t1/2], area
under the curve [AUC], steady-state volume of distribution) [4,5].
PD results were also similar between the 2 studies, with adminis-
tration on both schedules resulting in 70–80% proteasome
QDx2 – 28-day cyclea
(all studies except CARMYSAP, CLARION, CHAMPION-1, and NCT01857115)
QDx2 – 42-day cycle 
(CARMYSAP, CLARION)
D22/D23 D29/D30
QW – 28-day cycle 
(CHAMPION-1, NCT01857115)
Week 1 Week 2 Week 3: rest Week 4 Week 5 Week 6: rest
D1/D2 D8/D9
D15/D16
Week 1 Week 2 Week 3 Week 4: rest
D1/D2 D8/D9
D15
Week 1 Week 2 Week 3 Week 4: rest
D1 D8
Fig. 2. Carﬁlzomib schedules examined in completed and ongoing trials. Carﬁlzomib has been administered using a variety of schedules in completed and ongoing trials.
aCorresponds to the carﬁlzomib administration schedule approved by the United States Food and Drug Administration [11]. Recommended cycle 1 dose is 20 mg/m2; if
tolerated, it is recommended to increase dose to 27 mg/m2 for cycle 2 and subsequent cycles. D, day; QD, consecutive days; QW, once-weekly dosing.
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at carﬁlzomib doses of 15 mg/m2 and higher [4,5].
Efﬁcacy
Although not a primary objective of the initial phase I trials,
encouraging objective responses were observed in both studies.
In the 001 study, 4 responses (minimal response or better) were
noted in patients with MM (n = 2), Waldenström’s macroglobulin-
emia (n = 1), and mantle cell lymphoma (n = 1) [4]. In the 002
study, 8 responses were observed in patients with MM (n = 7)
and Waldenström’s macroglobulinemia (n = 1) [5].
Implications of phase I ﬁndings on phase II dosing and administration
schedule
The results from the 2 phase I studies suggested that consecu-
tive-day dosing had antitumor efﬁcacy, regardless of the schedule
used (QD  2 or QD  5), corroborating preclinical evidence for sub-
stantial proteasome inhibition with either regimen [1]. In addition,
the dose-escalation/expansion portions of the phase I trials allowed
detailed evaluation of safety at each dosing level. Taking the safety
ﬁndings and the preliminary efﬁcacy data together, a more favor-
able risk-beneﬁt proﬁle was observed with the QD  2 schedule
compared with the QD  5 schedule. Thus, the QD  2 schedule
was chosen for further exploration in phase II studies [6–9].
Concerns about TLS and ﬁrst-dose-like effects observed in 001
and with the 20/27-mg/m2 dosing schedule in 002 led to the con-
servative selection of the 20-mg/m2 dose of carﬁlzomib for the ﬁrst
pilot phase II study (PX-171-003-A0 [003-A0]). In addition, pro-
phylactic measures (prehydration and administration of very-
low-dose dexamethasone [4 mg] in cycle 1) were implemented
to mitigate against these potential adverse events [6].Phase II studies
PX-171-003-A0 and PX-171-003-A1 (NCT00511238)
While the 002 trial was still ongoing, the phase II 003-A0 pilot
study was initiated in August 2007 (FPFV) in patients with relapsed
and refractory MM. To be eligible, patients were required to have
immunoglobulin (Ig) G (IgG) or IgA MM that was relapsed andrefractory after at least 2 prior treatment regimens that must have
included the proteasome inhibitor bortezomib and an immuno-
modulatory agent (see Table 1). Following the initial ﬁndings from
002, 20-mg/m2 carﬁlzomib was administered IV (QD  2) for a
minimum of 2 cycles (Fig. 2); patients with stable disease or better
could continue to receive treatment for a maximum of 12 cycles.
Based on emerging preclinical toxicity data demonstrating a reduc-
tion in the risk of ﬁrst-dose-like effects with longer infusion
durations (Onyx Pharmaceuticals, unpublished results), the
administration time used in 001 and 002 was increased from
1–2 min to 2–10 min in 003-A0 as well as other studies initiated
around the same time (e.g., 003-A1, PX-171-004 [004], and
PX-171-005 [005]).
In the 46 patients studied in 003-A0, carﬁlzomib (20 mg/m2)
was well tolerated and ﬁrst-dose-like effects were not observed
[6]. Importantly, the PD parameters were similar to those observed
in the 2 phase I studies. The dose and QD  2 schedule demon-
strated encouraging efﬁcacy with an overall response rate (ORR)
of 16.7% (95% conﬁdence interval [CI], 7.0–31.4).
During the course of 003-A0, data from the dose-expansion
phase of the 002 study became available, demonstrating the safety
and tolerability of carﬁlzomib on the same schedule, but with a
dose of 27 mg/m2 starting on day 8 of cycle 1 for patients who
had tolerated the 20-mg/m2 dose. In addition, preliminary re-
sponse data from both phase I studies suggested that higher doses
might be more efﬁcacious. The 003-A0 pilot study was subse-
quently amended (003-A1) in July 2008 to permit escalated dosing
to 27 mg/m2 starting with cycle 2 (dose escalation would subse-
quently be introduced at day 8 of cycle 1 in later studies, when
dose escalation was found to be well tolerated). The same QD  2
dosing schedule and TLS prophylaxis measures were used in 003-
A1 as in the original 003-A0 study [7]. The study cohort was
expanded and ultimately led to the enrollment of 266 patients. Eli-
gibility criteria for 003-A1 were identical to those for 003-A0, with
the exception that patients with IgE or IgD MM were also eligible
for enrollment [11]. No differences in tolerability were observed
relative to the 003-A0 study and, importantly, there were no inci-
dents of TLS following the implementation of further reﬁned pro-
phylaxis guidelines (including the option to receive prophylactic
allopurinol). Patients in the 003-A1 study who received higher
doses of carﬁlzomib (27 mg/m2) appeared to experience improved
response rates relative to 003-A0 (ORRs of 23.7% and 16.7%, respec-
tively) [7]. These ﬁndings would ultimately form the foundation of
786 A.J. Jakubowiak / Cancer Treatment Reviews 40 (2014) 781–790the accelerated approval for carﬁlzomib in the United States for
this difﬁcult-to-treat patient population.
PX-171-004 (NCT00530816)
The 004 study (FPFV, September 2007; LPLV, January 2011) ran
concurrently with the 002, 003-A0, and 003-A1 studies. Patients
with MM who had responded to standard ﬁrst-line therapy and
had relapsed and/or refractory disease after at least 1 (but no more
than 3) previous regimens were enrolled [8,9]. As with 003-A0 and
003-A1, concerns about the potential for TLS and ﬁrst-dose-like
effects led to an initial selection of the 20-mg/m2 dose for evalua-
tion, as well as the implementation of prophylactic measures,
including prehydration and very-low-dose dexamethasone (4 mg)
in cycle 1. Patients were treated with 20 mg/m2 carﬁlzomib admin-
istered IV over 2–10 min QD  2 in 28-day cycles for a maximum
of 12 cycles. The study initially enrolled patients irrespective of
previous exposure to bortezomib. In 35 bortezomib-treated
patients, carﬁlzomib was well tolerated and did not exacerbate
preexisting peripheral neuropathy. Importantly, TLS and ﬁrst-
dose-like effects were not observed. The ORR was 17.1% and the
clinical beneﬁt response rate was 31.4%, demonstrating the efﬁcacy
of this dose and schedule [8].
Based on encouraging safety and efﬁcacy results from 002 at
27 mg/m2, the decision was made to increase the dose of carﬁlzo-
mib in the 004 study (similar to the study amendment made to
003-A0). Thus, patients who tolerated 20 mg/m2 carﬁlzomib dur-
ing cycle 1 received 27 mg/m2 over 2–10 min beginning in cycle
2. To distinguish 004 from the 003-A1 study, which also adminis-
tered 20/27 mg/m2 carﬁlzomib to patients with relapsed or refrac-
tory MM, a study amendment in December 2008 restricted
enrollment to those patients who had not been previously exposed
to bortezomib (i.e., ‘‘bortezomib-naive’’ patients), ultimately
enrolling 129 patients [9]. No differences in tolerability were ob-
served relative to the bortezomib-treated patients in 004 [8,9].
Two cases of TLS were observed during cycle 1 in patients treated
at 20 mg/m2; after these events occurred, prophylactic hydration
was implemented on the basis of emerging safety results from
the 002 study, demonstrating success in limiting this adverse
event. Although the study was not designed or powered to make
comparisons between the dose cohorts with respect to efﬁcacy or
safety, it is nonetheless notable that incremental improvements
in efﬁcacy were observed between cohorts, with an ORR of 42.4%
(95% CI, 29.6–55.9) for 20 mg/m2 and 52.2% (95% CI, 39.7–64.6)
for 20/27 mg/m2 [9]. Similar improvements were also seen in pro-
gression-free survival (8.2 months for 20 mg/m2 and not reached
for 20/27 mg/m2). To place these data into context, response rates
of roughly 40% have been reported with bortezomib monotherapy
in 2 phase III studies in patients with relapsed or refractory MM
[12,13].
Overall, the results of 004 suggest that carﬁlzomib is generally
tolerable and active in patients with relapsed and/or refractory
MM, with higher activity observed in patients who are less heavily
pretreated. Similar to what was observed in 003-A1, there was an
apparent increase in efﬁcacy in 004 at the 27-mg/m2 target dose
compared with 20 mg/m2. A pooled analysis of data from the
003-A0, 003-A1, and 004 trials would later show a signiﬁcant
dose–response relationship with single-agent carﬁlzomib treat-
ment, resulting in a 1.28-fold (95% CI: 1.17–1.40; p < 0.001)
increase in the odds of achieving a partial response or better for
each 1 mg/m2 increase in carﬁlzomib dose (equivalent to a 5.52-
fold increase in the odds of achieving a response if the average dose
increased from 20 mg/m2 to 27 mg/m2) [14]. Similar results were
also observed after adjusting for various baseline prognostic covar-
iates across studies (e.g., International Staging System stage,
female sex, and higher hemoglobin level) for the primary end pointof ORR (p < 0.001), as well as the secondary end points of duration
of response (p < 0.001), progression-free survival (p < 0.001), and
overall survival (p < 0.001).PX-171-005 (NCT00721734)
The phase II trial 005 (see Table 1) ran from December 2008
(FPFV) until December 2010 (LPLV) in parallel with the 002, 003-
A0, 003-A1, and 004 studies. The entry criteria were identical to
those established for the 003-A1 study, with the exception that
patients with varying degrees of renal function were enrolled,
ranging from normal renal function to patients requiring chronic
hemodialysis [10]. As in 003-A1 and 004, patients received car-
ﬁlzomib by IV infusion over 2–10 min QD  2 for a maximum of
12 cycles. As the PK and safety proﬁle of carﬁlzomib had not been
previously evaluated in patients with renal insufﬁciency or renal
dysfunction, a starting dose of 15 mg/m2 in cycle 1 was selected.
If the dose was tolerated, it was increased to 20 mg/m2 in cycle 2
and to 27 mg/m2 in cycle 3 and beyond. First-dose and TLS prophy-
laxis measures were identical to those of the amended 003-A1 and
004 bortezomib-naive studies.
No differences in tolerability were noted among patients with
varying degrees of renal impairment. Notably, TLS and ﬁrst-dose-
like reactions were not observed. Efﬁcacy results were encouraging
with an ORR of 25.5% and, when patients were grouped by renal
function, responses were evident across all groups.Phase Ib/II study of carﬁlzomib combined with lenalidomide
and low-dose dexamethasone
PX-171-006 (NCT00603447)
Based on preclinical and clinical data supporting the combina-
tion of proteasome inhibitors with immunomodulatory drugs and
low-dose dexamethasone [15–18], the phase Ib/II study PX-171-
006 (006) was initiated in June 2008 to evaluate carﬁlzomib in
combination with lenalidomide and dexamethasone (CRd) in pa-
tients with relapsed or progressive MM (Table 2). Patients were
treated with CRd in 28-day cycles. Carﬁlzomib was given as a
2–10-min IV infusion QD  2. Lenalidomide was given orally
(10–25 mg/day) on days 1–21, and oral dexamethasone (40 mg)
was given once weekly. The study enrolled patients in dose-escala-
tion cohorts (carﬁlzomib dose range: 15–27 mg/m2) and a dose-
expansion cohort (20/27 mg/m2). A total of 84 patients were
enrolled, including those previously treated with bortezomib
(77% of patients; 18% refractory) and/or lenalidomide (70% of pa-
tients; 35% refractory). As the MTD was not reached during the
dose-escalation phase, all patients in the dose-expansion cohort
(n = 52) received the maximum planned dose of 20 mg/m2 carﬁlzo-
mib on days 1 and 2 and 27 mg/m2 thereafter (i.e., from cycle 1 day
8). The trial is anticipated to be completed in 2014 (as of November
2013, 2 patients remain on CRd treatment) [19]. After a median fol-
low-up of 32.7 months, the ORR was 69.0% overall and 76.9% in
patients who received the maximum planned dose of carﬁlzomib
(20/27 mg/m2). Median progression-free survival was 11.8 months
overall and 15.4 months in patients receiving the maximum
planned dose. Taken together, these ﬁndings suggest a potential
relationship between dose and response, supporting similar
emerging data from 003-A0, 003-A1, and 004 [14]. Notably,
response rates and progression-free survival, especially at MTD,
compare favorably with those reported for patients treated with
lenalidomide and dexamethasone [20–22]. Grade 3/4 adverse
events following CRd use were similar to those from earlier studies
using single-agent carﬁlzomib at the 20/27-mg/m2 dose (including
a low rate [1%] of grade 3/4 peripheral neuropathy), demonstrating
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MM.Phase Ib/II study of prolonged infusion and higher doses
PX-171-007 (NCT00531284)
The PX-171-007 (007) study was initially activated in Septem-
ber 2007 to evaluate the safety and efﬁcacy of carﬁlzomib in
patients with advanced solid tumors, and included dose escalation
up to 36 mg/m2 administered IV over 2–10 min QD  2 [23]. This
higher maximum intended dose was justiﬁed by emerging clinical
evidence of a possible dose–response relationship, along with the
absence of an MTD in other carﬁlzomib trials and the successful
mitigation of TLS and ﬁrst-dose-like effects with prophylactic
interventions. After initiation of 007, preclinical studies demon-
strated that a 30-min infusion of 8 mg/kg carﬁlzomib in rats
resulted in a 28-fold lower Cmax relative to an IV bolus injection,
while other PK parameters and proteasome inhibition remained
comparable [24]. In addition, while 44% mortality was observed
with IV bolus administration in animals, the 30-min infusion was
well tolerated and did not result in any deaths. Based on these
results, it was hypothesized that prolonging the infusion time
may improve safety and possibly enhance efﬁcacy by allowing
patients to receive higher doses than those previously evaluated
(i.e., >27 mg/m2). To test this hypothesis, 007 was amended in
May 2009 to enroll patients with relapsed or refractory MM, and
to administer carﬁlzomib as a prolonged 30-min infusion with
dose escalation beyond 36 mg/m2. Carﬁlzomib was administered
on a QD  2 schedule, in which doses on days 1 and 2 of cycle 1
were 20 mg/m2 followed by cohort escalation to 36, 45, 56, or
70 mg/m2. Prior to carﬁlzomib infusion, very-low-dose dexameth-
asone (4 mg for carﬁlzomib doses 6 45 mg/m2 or 8 mg for carﬁlzo-
mib doses > 45 mg/m2) was given as premedication to reduce the
risk of potential infusion-related reactions (Papadopoulos et al.
unpublished results). The results from the dose-escalation phase
of 007 established 20/56 mg/m2 as the MTD, whereupon this
cohort was further expanded to a total of 24 patients. The ORR
for the expanded 20/56-mg/m2 cohort was 60%. Supporting the
preclinical ﬁndings of dose proportionality, PK analysis showed a
proportional increase in Cmax and AUC with increasing dose, but
no effect on t1/2 or carﬁlzomib clearance (Papadopoulos K et al.
unpublished results).
In 2011, 007 was amended again to examine the tolerability and
efﬁcacy of carﬁlzomib doses higher than 27 mg/m2 (administered
via a 30-min infusion) in patients with MM when combined with
low-dose dexamethasone (40 mg/week). In the amended study,
the 20/45-mg/m2 and 20/56-mg/m2 cohorts were expanded;
patients received carﬁlzomib QD  2 (as in the previous amend-
ment) and low-dose dexamethasone (40 mg/week). Among
patients treated with this combination (N = 22), the ORR was
60.0% and the safety proﬁle was found to be consistent with
single-agent carﬁlzomib at comparable doses (Papadopoulos
et al. unpublished results).Phase I/II trial of carﬁlzomib combined with melphalan-
prednisone
CARMYSAP (NCT01279694)
In many countries outside the United States, particularly in Eur-
ope, melphalan and prednisone in combination with a third agent
(e.g., bortezomib or thalidomide) is considered a standard treat-
ment regimen for transplant-ineligible patients with newly diag-
nosed MM. There are a limited number of approved combinationregimens available, however, for elderly patients who are newly
diagnosed but are not candidates for stem cell transplantation.
Thus, the phase I/II CARMYSAP study (NCT01279694) was initiated
in France to assess the safety and efﬁcacy of carﬁlzomib when
combined with melphalan and prednisone (CMP) in patients with
newly diagnosed MM who were aged >65 years (see Fig. 1 and
Table 1) [25]. Combining melphalan and prednisone with bortezo-
mib (VMP) was effective in the VISTA trial, yet a higher rate of ad-
verse events was observed compared with patients who received
melphalan and prednisone alone, including an increased rate of
peripheral neuropathy (44% vs. 5%; all grades, respectively) [26].
Given the emerging data that single-agent carﬁlzomib induced a
low rate of new-onset peripheral neuropathy and appeared not
to exacerbate existing peripheral neuropathy [7,27], it was hypoth-
esized that CMP may be better tolerated than VMP in elderly
patients with newly diagnosed MM.
The CARMYSAP study was initiated in October 2010 and is
ongoing at the time of writing. In the phase I portion of the study,
20 mg/m2 carﬁlzomib was given on days 1 and 2 of cycle 1, fol-
lowed by dose escalation to a maximum planned dose of 45 mg/
m2 infused over 30 min. While other QD x 2 schedules utilize a
28-day cycle in which carﬁlzomib is administered for 3 weeks
followed by 1 rest week, CARMYSAP uses a 42-day cycle in which
carﬁlzomib is administered for 2 weeks followed by 1 rest week, a
pattern that is repeated twice per cycle (i.e., dosing on days 1, 2, 8,
9, 22, 23, 29, and 30) for 9 cycles (see Fig. 2). The use of a 42-day
cycle in CARMYSAP was designed to mimic the dosing schedule
of VMP used in the VISTA trial. Oral melphalan (9 mg/m2) and
prednisone (60 mg/m2) are also given on days 1–4. As of January
2013, 69 patients have been enrolled. The MTD for carﬁlzomib
on this schedule has been established at 20/36 mg/m2 [28]. An
ORR of 89% was reported with CMP, which compares favorably
with results reported for other melphalan and prednisone-based
regimens (ORR range: 71% to 81%) [26,29,30]. Importantly, CMP
appears to be well tolerated in elderly patients with newly diag-
nosed MM, with no reports of grade P2 peripheral neuropathy
[25].Application of ﬁndings from phase I and II trials towards
ongoing studies
Despite advances in the treatment of MM over the past decade,
the disease remains incurable; most patients eventually relapse
and exhaust all available treatment options [31]. The need for
new therapies is clear, but so is the need for understanding the
optimal use of available therapies to maximize patient beneﬁt. This
includes evaluating dosing and administration schedules and
combination partners to achieve an appropriate balance between
efﬁcacy and safety/tolerability.
As is common in drug development, the optimal dosing sche-
dule and administration of carﬁlzomib have evolved as the drug
has progressed through clinical trials and with continued preclini-
cal investigation. In the case of carﬁlzomib, a QD  2 dosing sche-
dule was investigated in phase II trials based on 1) preclinical
evidence demonstrating greater antitumor activity with sustained
proteasome inhibition, and 2) favorable safety and tolerability ver-
sus a QD  5 dosing schedule in preclinical studies and phase I
clinical studies. Efﬁcacy and safety results from 003-A1 and safety
data from 003-A0, 004, and 005 led to the establishment of a dos-
ing and administration schedule that supported the US accelerated
approval of carﬁlzomib in patients with relapsed and refractory
MM in July 2012 (see Fig. 2). In the completed phase II studies,
higher doses were administered by modifying the dosing schedule;
a lower dose (e.g., 20 mg/m2) was administered during the ﬁrst
week of treatment, followed by administration of the target dose
Table 3
Application of key phase I and II results to dose and schedule in ongoing studies.
Study Phase Treatment Carﬁlzomib dose/schedule Patient population
PX-171–003-A1 II Carﬁlzomib 20/27 mg/m2 (QD x 2a) Relapsed and refractory MM
FOCUS (NCT01302392) III Carﬁlzomib vs best
supportive care
20/27 mg/m2 (QD x 2a) Relapsed and refractory MM
PX-171–006 Ib/II CRd 20/27 mg/m2 (QD x 2a) Relapsed or progressive MM
ASPIRE (NCT01080391) III CRd vs Rd 20/27 mg/m2 (QD x 2a) Relapsed MM
NCT01029054 I/II CRd Up to 36 mg/m2 (QD x 2a cycles 1–8; D1, 2, 15, 16 cycles 9+) Newly diagnosed MM
NCT01816971 II CRd Up to 36 mg/m2 (QD x 2a induction and consolidation;
D1, 2, 15, 16 maintenance)
Newly diagnosed MM
NCT01402284 II CRd 20/36 mg/m2 (QD x 2a) Newly diagnosed MM
NCT01572480 II CRd 20/36 mg/m2 (QD x 2a) Smoldering MM
CARMYSAP I/II CMP MTD: 20/36 mg/m2 (QD x 2b) Newly diagnosed, transplant-
ineligible MM
CLARION
(NCT01818752)
III CMP vs VMP 20/36 mg/m2 (QD x 2b) Newly diagnosed, transplant-
ineligible MM
NCT01346787 II CCyd 20/36 mg/m2 (QD x 2a) Newly diagnosed MM
NCT01857115 I/II CCyd Up to 20/70 mg/m2 (QWc) Newly diagnosed MM
PX-171–007 Ib/II Cd MTD: 20/56 mg/m2 (QD x 2a) Relapsed and/or refractory MMd
ENDEAVOR
(NCT01568866)
III Cd vs Vd 20/56 mg/m2 (QD x 2a) Relapsed MM
NCT01903811 II Cd 27 mg/m2 vs 56 mg/m2 (QD x 2a) Relapsed or refractory MM
CHAMPION-1
(NCT01677858)
I/II Cd Up to 88 mg/m2 (QWc) Relapsed or refractory MM
CCyd, carﬁlzomib, cyclophosphamide, and dexamethasone; Cd, carﬁlzomib and dexamethasone; CMP, carﬁlzomib, melphalan, and prednisone; CRd, carﬁlzomib, lenalido-
mide, and dexamethasone; D, day; MM, multiple myeloma; MTD, maximum tolerated dose; QD, consecutive days; QW, once-weekly dosing; Rd, lenalidomide and dexa-
methasone; Vd, bortezomib and dexamethasone; VMP, bortezomib, melphalan, and prednisone.
a D1, 2, 8, 9, 15, 16 of 28-day cycle.
b D1, 2, 8, 9, 22, 23, 29, 30 of 42-day cycle.
c D1, 8, 15 of 28-day cycle.
d Patients with solid tumors and refractory or rituximab-intolerant lymphoma were also enrolled.
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1, as evaluated in 006 and 007, demonstrated that earlier dose
escalation was also well tolerated. Given the apparent dose–
response effect that has been observed, it is possible that
additional patients in the early phase 1 and 2 studies may have
demonstrated responses if the carﬁlzomib dose had been escalated
at an earlier time point. Although a small number of TLS and
ﬁrst-dose-like effect cases were observed during the phase I and
the initial phase II studies, the use of prophylactic hydration,
allopurinol, and the addition of low-dose dexamethasone has since
reduced the incidence of these effects in later studies, as has
extending the infusion time.
Administration of carﬁlzomib over 30 min and adding a low
dose of dexamethasone enabled patients to receive higher doses
of carﬁlzomib in 007, with comparable tolerability to that seen
with lower doses and shorter infusion times (Papadopoulos et al.
unpublished results) [32,33]. These ﬁndings are consistent with a
dose–response relationship previously observed in phase I studies
and the phase II studies 003-A0, 003-A1, and 004 [4,5,14]. Interest-
ingly, increased immunoproteasome inhibition has been observed
with the higher dose of carﬁlzomib (20/56 mg/m2), and may be a
possible mechanism for the reported improvements in clinical
responses, as the immunoproteasome is known to be highly
expressed in myeloma cells [15,32].
Results from the studies described above have been used to
inform the carﬁlzomib regimens used in ongoing randomized, con-
trolled, phase III studies and investigator-sponsored trials (Table 3).
For example, knowledge from the 003-A1 study was applied to the
dosing schedule in the phase III randomized FOCUS trial
(NCT01302392), which is investigating single-agent carﬁlzomib
versus best supportive care in relapsed and refractory MM. This
trial has been underway since September 2010 (FPFV), with
primary completion anticipated for the ﬁrst half of 2014 [34].
The CRd regimen that was used in 006 is being assessed in the
phase III randomized trial ASPIRE (NCT01080391) in comparison
with lenalidomide and dexamethasone in relapsed MM [35].ASPIRE began enrolling patients in June 2010 and primary comple-
tion is anticipated for the ﬁrst half of 2014. CRd is also being
investigated in earlier lines of treatment in a number of investiga-
tor-sponsored trials. In a phase I/II trial, CRd treatment in patients
with newly diagnosed MM (NCT01029054) was shown to have
excellent efﬁcacy and depth of response and appeared to be well
tolerated [33,36]. Patients received up to 36 mg/m2 carﬁlzomib
QD  2 (in cycle 9 and beyond, carﬁlzomib administration on days
8 and 9 was omitted) over a 30-min infusion, and patients had the
option to receive stem cell transplantation after cycle 4. A separate
phase II trial is further exploring use of the CRd regimen before and
after stem cell transplantation in patients with newly diagnosed
MM (NCT01816971). Similar to the initial phase I/II trial, patients
receive a target dose of 36 mg/m2 carﬁlzomib administered
QD  2 (during maintenance therapy, carﬁlzomib administration
on days 8 and 9 is omitted). CRd is also being investigated in
patients with newly diagnosed MM when followed by extended
lenalidomide dosing (NCT01402284) [37], and in patients with
smoldering MM (NCT01572480) [38]; in both studies, carﬁlzomib
is being administered at 36 mg/m2 QD  2 over 30 min.
Tolerability and efﬁcacy ﬁndings from the CARMYSAP study
[25] have supported additional investigations into combining car-
ﬁlzomib with an alkylating agent and corticosteroid. The phase III
randomized trial CLARION (NCT01818752) is comparing CMP ver-
sus VMP in patients with newly diagnosed MM who are ineligible
for stem cell transplantation, using the same doses and schedule as
the CARMYSAP study. In addition, carﬁlzomib combined with
cyclophosphamide and dexamethasone (CCyd) is being investi-
gated in phase I and II trials, as cyclophosphamide is considered
to lack the cumulative hematologic toxicity of melphalan and
may be a better-tolerated alternative [39,40]. CCyd is also being
evaluated in patients with newly diagnosed MM, with carﬁlzomib
administered QD  2 at a dose of 20/36 mg/m2 (NCT01346787)
[41] or weekly in doses up to 20/70 mg/m2 (NCT01857115).
The safety results from the amended 007 study provided the
basis for the doses and schedules that are being used in a number
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(NCT01568866) is comparing a 30-min infusion of 20/56 mg/m2
carﬁlzomib plus dexamethasone versus bortezomib plus dexa-
methasone in patients with relapsed MM. The study was initiated
in June 2012, with primary completion expected for January 2015.
Additional studies are investigating the use of dexamethasone in
combination with different doses and schedules of carﬁlzomib,
and use of the combination regimen in earlier lines of treatment.
For example, a phase II study is examining the efﬁcacy of dexa-
methasone in combination with 2 different doses of carﬁlzomib
(27 mg/m2 vs 56 mg/m2 QD  2) in patients with relapsed or
refractory MM (NCT01903811). Meanwhile, the ongoing phase I/
II study CHAMPION-1 (NCT01677858) is examining dexametha-
sone combined with higher carﬁlzomib doses (20/45, 20/56, 20/
70, and 20/88 mg/m2, as a 30-min infusion) that are administered
once-weekly in patients with relapsed or refractory MM. At the
2013 American Society of Hematology Annual Meeting and Exposi-
tion, the study investigators reported that the MTD of once-weekly
carﬁlzomib administered in combination with dexamethasone
(40 mg) was 70 mg/m2 [42]. An ORR of 60% was observed in
patients receiving the MTD (n = 15). At the MTD, the regimen
was found to have an acceptable safety and tolerability proﬁle,
with infrequent grade P3 adverse events, a low rate of discontin-
uation due to adverse events, and no carﬁlzomib dose reductions.
Conclusion
In summary, results from early preclinical and clinical studies
have informed ongoing phase II and III randomized trials that are
investigating carﬁlzomib in a number of different dosing regimens,
schedules, and treatment combinations. As with any therapeutic,
the optimization of dosing regimens and schedules is an important
step in realizing the optimal risk-beneﬁt proﬁle of carﬁlzomib. Fur-
ther trials of carﬁlzomib combinations in various MM settings are
underway, as are studies of its efﬁcacy and safety in subsets of
patients such as those with high-risk cytogenetics [43]. These ﬁnd-
ings will undoubtedly inform healthcare professionals, patients,
and their caregivers about the activity of single-agent carﬁlzomib
and its use in combination with other agents in different patient
populations. In addition, ﬁndings from ongoing studies may help
to minimize the need for dose reductions and treatment discontin-
uations, which may ultimately lead to deeper and more durable
responses.
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